Abstract: The invention provides methods and compositions (e.g., pharmaceutical compositions) for treating breast cancer (e.g., TNBC (e.g., eTNBC)) in a subject. In some aspects, the methods include administering a treatment regimen including a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody (e.g., atezolizumab) or an anti-PD-1 antibody), a taxane (e.g., nab-paclitaxel or paclitaxel), an anthracycline (e.g., doxorubicin or epirubicin), and an alkylating agent (e.g., a nitrogen mustard derivative (e.g., cyclophosphamide)) to the subject. In some aspects, the treatment regimen increases the subject's likelihood of having a pathologic complete response (pCR) as compared to treatment with the taxane, the anthracycline, and the alkylating agent without the PD-1 axis binding antagonist. Also provided are pharmaceutical compositions for use in treating breast cancer (e.g., TNBC (e.g., eTNBC)) in a subject.

Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.